Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France - 20/11/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Pharmacovigilance for Covid 19 vaccines was organized. |
• | Cooperation with the European agency was harmonious. |
• | All significant adverse events were thoroughly investigated. |
Abstract |
As of February 2022, more than 130 million Covid vaccine doses had been distributed in France. During the first year of relevant vaccination, 128,766 adverse events (AE) were reported and analysed, as compared to an average of 40,000 per year for all drugs combined in the pre-pandemic years. A weekly monitoring committee was set up. Through enhanced pharmacovigilance, by February 2022, 49 safety signals had been identified nationwide and submitted to the EMA. For example, very few cases of myocarditis and pericarditis were reported. In children, 9 multisystem inflammatory syndromes were reported.
Le texte complet de cet article est disponible en PDF.Keywords : Covid 19, Vaccine, Adverse events, Pharmacovigilance, Myocarditis
Plan
Vol 52 - N° 8S
P. S16-S18 - novembre 2022 Retour au numéro
Article précédent
- What progress has been made in treatment of immunocompromised COVID-19 patients?
- F. Ader, J. Bauer
- Attitudes of French adults toward COVID-19 vaccination
- J.K. Ward, J. Bauer
Bienvenue sur EM-consulte, la référence des professionnels de santé.